Similar to the findings in the CheckMate 040 trial, no significant relationship was identified between the efficacy measures and the density or percentage of T cells expressing CD3+, CD4+, CD8+, and FoxP3+, CD20+ cells, or M2 macrophages in either the tumor or stromal areas. This evidence concerns the gene CD8A and neoplasm.